Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) AI Stock Analysis

• Market Cap: AU$63.32B
• Dividend Yield: 0.75%
• Average Volume (3M): 856.91K
• Price to Earnings (P/E): 29.2
• Beta (1Y): 0.99
• Revenue Growth: 11.26%
• EPS Growth: 39.47%
• Country: AU
• Employees: 9,980
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.39
• Shares Outstanding: 1,466,273,900
• 10 Day Avg. Volume: 1,096,878
• 30 Day Avg. Volume: 856,915
• PEG Ratio: 5.41
• Price to Book (P/B): 6.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 23.82
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 12.65
• Enterprise Value/Ebitda: 5.60
• 1Y Price Target: AU$45.42
• Price Target Upside: 5.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 78 Outperform
• Price Target: AU$48.00 ▲(11.94%Upside)

ResMed's robust financial performance and positive earnings call are the primary drivers of its strong overall score of 78. While technical indicators suggest potential overbought conditions, the company's strategic focus and recent achievements support a positive outlook. Valuation remains a concern, with a high P/E ratio limiting attractiveness on a purely value basis.

Positive Factors

Financial Health

Share buybacks worth US$75 million were executed during the quarter, which can signal confidence in the company's financial health.

Financial Performance

The company reported strong devices growth, contributing to a solid Q2 performance with earnings exceeding expectations.

Stock Valuation

Upgrade to Buy on reasonable valuation, strong EPS growth, FCF, and no debt by FY end.

Negative Factors

Growth Constraints

Healthcare systems’ capacity constraints will likely keep a lid on new patients growth.

Market Sentiment

RMD’s share price has historically reacted negatively to news flow on GLP-1s.

Sales Performance

Revenue from the Rest of World masks and SaaS was below consensus, indicating some areas of underperformance.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model

Company Description

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

How the Company Makes Money

ResMed Inc. generates revenue through the sale of its respiratory care devices, such as continuous positive airway pressure (CPAP) machines, masks, and related accessories used for the treatment of sleep apnea and other respiratory disorders. In addition to device sales, ResMed earns income from its software-as-a-service (SaaS) solutions, which include cloud-based platforms for healthcare providers to manage patient data and treatment efficacy. The company also benefits from strategic partnerships with healthcare organizations and ongoing investments in research and development to enhance its product offerings and expand its market reach. Factors contributing to ResMed's earnings include an increasing global awareness of sleep-related health issues and a growing demand for remote patient monitoring and management solutions.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview

Summary

ResMed Inc exhibits a well-rounded financial performance with strong revenue and profit growth, enhanced margins, and a solid balance sheet. Improved cash flow metrics underscore the company's ability to sustain operations and invest in growth opportunities. Continued vigilance on leverage is advised to maintain financial flexibility.

Income Statement

The income statement shows strong performance with consistent revenue growth. From 2021 to TTM 2025, revenue grew from $2.96 billion to $5.02 billion. Gross profit margin has been stable around 58-59%, with a notable increase in net profit margin from 16% in 2021 to 26% in TTM 2025. EBIT and EBITDA margins have also improved, indicating effective cost management and operational efficiency.

Balance Sheet

The balance sheet is robust, with a strong equity base growing from $2.49 billion in 2021 to $5.55 billion in TTM 2025. The debt-to-equity ratio has decreased significantly, improving financial stability. However, the equity ratio is moderately high, warranting watchfulness over leverage despite the reduction in total debt.

Cash Flow

Cash flow statements reveal solid cash flow generation, with operating cash flow growing significantly. Free cash flow increased from $0.38 billion in 2020 to $1.56 billion in TTM 2025, reflecting efficient capital expenditure and strong cash management. Both operating and free cash flow to net income ratios are healthy, supporting the company’s capacity to fund operations and growth.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.02B	4.69B	4.22B	3.58B	3.20B	2.96B
Gross Profit	2.94B	2.66B	2.36B	2.02B	1.84B	1.72B
EBITDA	1.71B	1.53B	1.36B	1.18B	1.10B	990.43M
Net Income	1.31B	1.02B	897.56M	779.44M	474.50M	621.67M
Balance Sheet
Total Assets	7.57B	6.87B	6.75B	5.10B	4.73B	4.59B
Cash, Cash Equivalents and Short-Term Investments	932.71M	238.36M	227.89M	273.71M	295.28M	463.16M
Total Debt	839.77M	873.93M	1.58B	917.55M	793.72M	1.30B
Total Liabilities	2.02B	2.01B	2.62B	1.74B	1.84B	2.09B
Stockholders Equity	5.55B	4.86B	4.13B	3.36B	2.89B	2.50B
Cash Flow
Free Cash Flow	1.56B	1.29B	559.30M	195.11M	619.89M	696.32M
Operating Cash Flow	1.65B	1.40B	693.30M	351.15M	736.72M	802.25M
Investing Cash Flow	-112.84M	-269.78M	-1.16B	-229.92M	-158.46M	-179.86M
Financing Cash Flow	-835.65M	-1.12B	422.87M	-128.36M	-764.63M	-317.29M

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RMD, the sentiment is Positive. The current price of 42.88 is above the 20-day moving average (MA) of 40.26, above the 50-day MA of 39.32, and above the 200-day MA of 37.47, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 78.85 is Negative, neither overbought nor oversold. The STOCH value of 76.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RMD.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	78 Outperform	AU$63.32B	29.20	26.44%	0.75%	11.26%	39.47%
Sector *	57 Neutral	£5.17B	5.82	-64.95%	2.28%	32.38%	-7.27%
S5YA	―	€18.71B	―	-1.63%	0.39%	―	―
CHEOF	―	$13.21B	53.69	20.61%	1.38%	―	―
PMCUF	―	$21.21B	325.99	52.66%	0.15%	―	―
RMSYF	―	$5.65B	1,113.18	0.52%	2.05%	―	―
SHL	73 Outperform	AU$13.51B	24.00	6.86%	3.91%	10.15%	6.20%

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events

ResMed CEO Executes Stock Transactions Under Rule 10b5-1 Plan

ResMed Inc.’s CEO, Michael J. Farrell, executed transactions involving the company’s common stock under a pre-established Rule 10b5-1 plan. This plan allows for the planned sale or purchase of securities, providing a structured approach to managing stock transactions. The transactions involved the acquisition and subsequent sale of 8,009 shares, reflecting strategic financial management by the company’s leadership. These actions are part of a broader strategy to optimize stock holdings and align with corporate governance practices, potentially impacting stakeholder perceptions and market dynamics.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc. Officer Plans Sale of Common Stock Under Rule 144

ResMed Inc. has announced a proposed sale of securities under Rule 144, with Michael J. Farrell, an officer and director of the company, planning to sell 8,009 shares of common stock. The sale is expected to occur on July 7, 2025, with the aggregate market value of the shares estimated at approximately $2,056,075.99. This transaction follows previous sales by Farrell in April and May 2025, which generated gross proceeds of over $3.6 million. The announcement may impact stakeholder perceptions and market dynamics, given Farrell’s significant role within the company.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed CFO Reports Changes in Stock Ownership

ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported changes in his beneficial ownership of the company’s stock, as per a transaction plan under Rule 10b5-1. The transactions involved acquiring and disposing of shares, reflecting strategic financial management and adherence to regulatory compliance, potentially impacting investor perceptions and market dynamics.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc. Announces Stock Transaction by Global General Counsel

ResMed Inc., a company involved in the healthcare industry, focuses on the development and manufacturing of equipment related to sleep disorders and respiratory care. The recent filing indicates a transaction involving the sale of common stock by Michael J. Rider, Global General Counsel and Secretary, under a pre-established Rule 10b5-1 plan. This transaction reflects changes in beneficial ownership and may have implications for the company’s stock market activities.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Reports Increase in CHESS Depositary Interests

Resmed Inc announced an increase in the number of CHESS Depositary Interests (CDIs) issued over quoted securities, with a net addition of 1,288,180 CDIs in June 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options and employee stock plans. The adjustments reflect the company’s ongoing efforts to manage its securities and optimize its capital structure, potentially impacting its market positioning and shareholder value.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Director Announces Further Share Sale

ResMed Inc has announced a proposed sale of securities under Rule 144, with a director, Peter C. Farrell, planning to sell 945 common shares through Merrill Lynch. This move follows previous sales of 6,000 shares over the past three months, indicating a continued divestment by the director. The sale is scheduled for July 2, 2025, and could potentially impact the company’s stock market performance and investor sentiment, given the significant role of the director in the company.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed to Announce Q4 Fiscal 2025 Earnings

Resmed Inc. has announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the New York Stock Exchange closes. The announcement includes a webcast for discussing the results, which may impact stakeholders by providing insights into the company’s performance and strategic direction.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Officer Files Notice for Stock Sale Under Rule 144

Resmed Inc has filed a notice of proposed sale of securities under Rule 144, indicating that Michael J. Rider, an officer of the company, plans to sell 66 shares of common stock. This filing is part of a series of transactions, with previous sales occurring in April and June 2025, reflecting ongoing stock management by company insiders. The sales are executed through Fidelity Brokerage Services LLC, and the transactions are part of restricted stock vesting, highlighting routine financial activities within the company.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc Reports Change in Beneficial Ownership

ResMed Inc has reported a change in beneficial ownership as per a transaction conducted under a Rule 10b5-1 plan. Peter C. Farrell, the Chairman Emeritus, disposed of 2,000 shares of ResMed common stock at a price of $247.32 per share, leaving him with a total of 69,218 shares. This transaction reflects ongoing strategic financial management within the company and may have implications for stakeholders regarding the company’s stock performance and executive shareholding patterns.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc Director Proposes Sale of Common Shares

ResMed Inc has filed a Form 144 indicating a proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing involves the sale of 2,000 common shares by Peter C. Farrell, a director of the company, with an aggregate market value of $500,000. The transaction reflects insider activity and may have implications for the company’s stock performance and investor perceptions.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Reports Decrease in CDI Issuance for May 2025

Resmed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for May 2025, with a reduction of 1,750,140 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock held on the NYSE. Additionally, there was a decrease in the total number of securities over which CDIs have not been issued, due to transfers between CDIs quoted on ASX and new share issues on the NYSE related to stock options and employee plans, as well as share repurchases.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan

ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a transaction involving the sale of 1,000 shares of ResMed common stock under a pre-established Rule 10b5-1 trading plan. This transaction, executed on June 2, 2025, reflects the CFO’s adherence to regulatory compliance while managing personal stock holdings. Such transactions are part of routine financial management and may not directly impact the company’s operational strategies or market position.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc. Officer Files Notice for Proposed Sale of Securities

ResMed Inc. has filed a Form 144 notice indicating the proposed sale of securities by Michael J. Rider, an officer of the company. The filing outlines the sale of 41 common shares with an aggregate market value of $9,994.98, scheduled for June 2, 2025. This transaction follows previous sales by Rider in March and April 2025, reflecting ongoing personal financial management activities. The announcement does not indicate any adverse information regarding ResMed’s current or future operations, suggesting stability in the company’s market position.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Officer Plans Sale of Common Stock

Resmed Inc has filed a notice of proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 1,000 shares of common stock. The sale is scheduled for June 2, 2025, with an aggregate market value of $243,780. This move follows previous sales by Sandercock in March and April 2025, reflecting ongoing transactions that may impact the company’s stock liquidity and stakeholder interests.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc. Files Conflict Minerals Disclosure Report for 2024

ResMed Inc. has filed a Specialized Disclosure Report, Form SD, in compliance with the Securities Exchange Act Rule 13p-1 for the reporting period of January 1 to December 31, 2024. The report addresses the company’s conflict minerals disclosure, detailing the reasonable country of origin inquiry process and its outcomes. This disclosure is significant as it reflects ResMed’s commitment to corporate governance and ethical sourcing, potentially impacting its reputation and stakeholder trust.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan

ResMed Inc. has reported a change in beneficial ownership, with Chief Financial Officer Brett Sandercock executing a transaction involving the sale of 3,644 shares of ResMed common stock at a price of $244.59 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan, highlighting a strategic financial decision within the company’s management. The transaction reflects ongoing management activities and may influence stakeholder perceptions regarding the company’s financial strategies.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Updates Dividend Exchange Rate for CDI Holders

Resmed Inc has announced an update regarding the foreign exchange rate for its upcoming dividend distribution to holders of CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange. The exchange rate has been set at 0.6400 U.S. dollars for 1.00 Australian dollar, resulting in a dividend of 0.0828 Australian dollars per CDI. The announcement also highlights the potential reduction in the default U.S. withholding tax from 30% to 15% for Australian residents, contingent upon the submission of the appropriate tax forms. This update may impact the financial returns for CDI holders and reflects Resmed’s ongoing commitment to transparent communication with its stakeholders.

ResMed Inc Reports Changes in CDIs and Securities for April 2025

ResMed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for April 2025, with a reduction of 9,500,350 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock on the NYSE. Additionally, there has been an increase in other securities due to stock options, restricted stock units, employee stock purchase plans, and share repurchases on the NYSE, reflecting the company’s ongoing financial and operational adjustments.